HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hillhouse Capital Related

527.947

+18.2853.59%

Number of Gainers:45

Number of Losers:7

Number of Flat:3

PE:- -

High:530.078

Open:509.680

Low:509.680

Close:509.662

Loading ...

LifeTech Scientific - Unit Subscribed for Principal-Protected Structured Deposits Issued by China Merchants Bank for RMB273 Mln

THOMSON REUTERS

JPMorgan Chase & Co's Long Position in H Shares of WuXi AppTec Decreases to 7.71% on Feb 21 From 8.58% - HKEX

THOMSON REUTERS

Haidilao International Holding Sees Insider Stock Selling

Simply Wall St.

China's HongShan hires ex-Bain Capital dealmaker in new Japan push, sources say

BUZZ-Budweiser Brewing hits 4-month peak on higher dividend payout

HBM Joint Venture Strikes Licensing Deal to Advance Novel CRH Therapies

MT Newswires Live

Calculating The Fair Value Of JD Health International Inc. (HKG:6618)

Simply Wall St.

Investors Met With Slowing Returns on Capital At Xtep International Holdings (HKG:1368)

Simply Wall St.

Hansoh Pharmaceutical Group's Anti-Hives Capsule Obtains Chinese Regulator's Approval for Clinical Trials

MT Newswires Live

Chinese Regulator Designates Hansoh Pharmaceutical Group's Injection as Breakthrough-Therapy Drug for Bone Cancer

MT Newswires Live

BRIEF-Hansoh Pharmaceutical Says NMPA Granted Approval For HS-20093

BRIEF-Hansoh Pharmaceutical Receives Clinical Trial Approval For Hs-10561 Capsules Issued By NMPA

Hansoh Pharmaceutical - Nmpa Granted Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate Hs-20093

THOMSON REUTERS

Hansoh Pharmaceutical - Clinical Trial Approval for Hs-10561 Capsules Issued by Nmpa

THOMSON REUTERS

Genor Biopharma - Co and Target Are in Course of Preparing New Listing Application

THOMSON REUTERS

The Returns At China Resources Beer (Holdings) (HKG:291) Aren't Growing

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1583/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1583"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","market":"HK","secType":"PLATE","nameCN":"Hillhouse Capital Related","latestPrice":527.9473,"timestamp":1741248510375,"preClose":509.66202,"halted":0,"volume":1057980231,"delay":0,"changeRate":0.035877,"change":18.285309,"pbRate":2.476973,"amount":21240321333,"amplitude":0.040024,"prevYearClose":446.93042,"fiveDayClose":516.603,"twentyDayClose":456.991,"turnoverRate":0.007626,"marketCap":2903806133248,"floatMarketCap":2322846109184,"peRate":34.369435},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","high":530.0783,"amplitude":0.040024,"preClose":509.66202,"low":509.67975,"pbRate":"2.476973","latestPrice":527.9473,"volume":1057980231,"delay":0,"open":509.67975,"prevYearClose":446.93042,"prevWeekClose":492.906,"prevMonthClose":492.906,"prevQuarterClose":446.93,"fiveDayClose":516.603,"twentyDayClose":456.991,"sixtyDayClose":476.209,"secType":"PLATE","market":"HK","turnoverRate":0.007626,"peRate":34.369435,"marketCap":2903806133248,"floatMarketCap":2322846109184,"timestamp":1741248510375,"nameCN":"Hillhouse Capital Related"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1583\",,,,undefined,":{"bkCode":"BK1583","up":45,"down":7,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1583\",pageSize:16,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514799098","title":"LifeTech Scientific - Unit Subscribed for Principal-Protected Structured Deposits Issued by China Merchants Bank for RMB273 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514799098","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514799098?lang=en_us&edition=fundamental","pubTime":"2025-02-27 18:05","pubTimestamp":1740650719,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI0VY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1600","01302","BK1100","BK1583"],"gpt_icon":0},{"id":"2514786598","title":"JPMorgan Chase & Co's Long Position in H Shares of WuXi AppTec  Decreases to 7.71% on Feb 21 From 8.58% - HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2514786598","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514786598?lang=en_us&edition=fundamental","pubTime":"2025-02-27 17:11","pubTimestamp":1740647476,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"e047f097f5c140fb593219bdbe008468","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI0SX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0216","LU0456842615.SGD","LU0320764599.SGD","LU1997245177.USD","LU2242644610.SGD","LU1046422090.SGD","LU2125910500.SGD","LU0052750758.USD","LU2488822045.USD","BK1141","LU2045819591.USD","BK1576","02359","LU0708995583.HKD","LU1997245094.SGD","BK1583","603259"],"gpt_icon":0},{"id":"2514846844","title":"Haidilao International Holding Sees Insider Stock Selling","url":"https://stock-news.laohu8.com/highlight/detail?id=2514846844","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514846844?lang=en_us&edition=fundamental","pubTime":"2025-02-27 11:10","pubTimestamp":1740625839,"startTime":"0","endTime":"0","summary":"Viewing insider transactions for Haidilao International Holding Ltd.'s ( HKG:6862 ) over the last year, we see that...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/4214000-choice1-main-header/1585186691957","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4214000-choice1-main-header/1585186691957"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/consumer-services/hkg-6862/haidilao-international-holding-shares/news/haidilao-international-holding-sees-insider-stock-selling","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1589","LU2488822045.USD","BK1604","06862","BK1233","BK1583","BK1591"],"gpt_icon":1},{"id":"2514002709","title":"China's HongShan hires ex-Bain Capital dealmaker in new Japan push, sources say","url":"https://stock-news.laohu8.com/highlight/detail?id=2514002709","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514002709?lang=en_us&edition=fundamental","pubTime":"2025-02-26 15:51","pubTimestamp":1740556261,"startTime":"0","endTime":"0","summary":"China's HongShan hires ex-Bain Capital dealmaker in new Japan push, sources sayBy Kane Wu and Julie Zhu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nL3N3OF00B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0048597586.USD","LU0345775950.USD","BK4585","LU0577902371.SGD","BK1583","LU0455707207.USD","LU1152091754.HKD","LU1688375341.USD","LU0823426308.USD","LU0823426480.USD","LU0456827905.SGD","LU0502904849.HKD","LU0823040885.USD","IE00BF5LJ272.USD","LU1046421795.USD","LU0348805143.USD","LU0231483743.USD","LU0499858602.USD","LU0307460666.USD","BK4504","LU0128525689.USD","SG9999002562.SGD","LU0672654166.SGD","LU0348816934.USD","LU0052756011.USD","BK4538","LU1188198961.HKD","LU1734074674.USD","LU1831875114.USD","LU1323998911.USD","LU1813983027.USD","LU0577902611.USD","LU0164865239.USD","LU0164880469.USD","LU0143863784.USD","BK4587","LU0149721374.USD","LU0251143458.SGD","LU2399975544.HKD","LU0561508036.HKD","LU0509642566.USD","LU0449509016.USD","LU0228659784.USD","LU0287142896.SGD","LU2257852520.SGD","LU1328615791.USD"],"gpt_icon":1},{"id":"2514960006","title":"BUZZ-Budweiser Brewing hits 4-month peak on higher dividend payout","url":"https://stock-news.laohu8.com/highlight/detail?id=2514960006","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514960006?lang=en_us&edition=fundamental","pubTime":"2025-02-26 14:55","pubTimestamp":1740552909,"startTime":"0","endTime":"0","summary":"BUZZ-Budweiser Brewing hits 4-month peak on higher dividend payout** Shares of Budweiser Brewing Company APAC 1876.HK jump as much as 13.5% to HK$8.90, highest since October 15, 2024** Stock last up 11.4%, on track for the biggest one-day pct gains since November 2020** Stock top pct gainer in Hang Seng Index .HSI, which is up 3.1%** The brewer says its 2024 net profit down 15% y/y to $726 mln with revenue down 7% y/y to $6.2 bln** However, company proposes $750 mln dividend, a 7% increase y/y, with final dividend increasing to 5.66 U.S. cents per share from 5.29 U.S. cents in 2023** Citi says BUD APAC's core NP fell largely in line with market expectations and the brewer lifting dividend payout ratio is positive with enhanced cash return to shareholders** Rivals also rise with China Resources Beer 0291.HK adding 2.9% and Tsingtao Brewery 0168.HK up 4.4%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nL2N3PH08D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0543330483.HKD","BK0196","BK1180","BK1610","BK1570","IE00B0169L03.USD","IE00B543WZ88.USD","LU2328871848.SGD","IE0008369823.USD","IE00B29SXG58.USD","LU0630378692.HKD","SG9999000459.SGD","00168","600600","BK1578","LU0197773673.USD","IE00BGV7N243.SGD","CRHKY","LU0762541174.USD","IE0008368742.USD","BK0188","LU0572944931.SGD","BK1521","IE00BPRC5H50.USD","LU0630378429.USD","LU0831093199.SGD","LU0327786744.USD","LU1794554557.SGD","LU1720050803.USD","LU0197773160.USD","01876","LU1328615791.USD","SG9999006514.SGD","IE00B031HY20.USD","LU0762540952.USD","BK1583","LU1023057109.AUD","BK0028","BK0215","BK0012","BK1604","LU0029875118.USD","LU1969619763.USD","LU0320764755.SGD","LU0359201612.USD","LU0128522157.USD","80291","00291","LU0359202008.SGD","BK1510"],"gpt_icon":0},{"id":"2514005902","title":"HBM Joint Venture Strikes Licensing Deal to Advance Novel CRH Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2514005902","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514005902?lang=en_us&edition=fundamental","pubTime":"2025-02-26 14:39","pubTimestamp":1740551973,"startTime":"0","endTime":"0","summary":"HBM Holdings'  joint venture with Boston Children's Hospital, HBM Alpha Therapeutics, agreed to collaborate with an unnamed business partner to advance novel therapies targeting corticotropin-releasing hormone or CRH for multiple disorders.Under the tie-up, the partner gets exclusive global rights to develop and commercialize HBM9013, an anti-CRH-neutralizing antibody. The license excludes China, Hong Kong, Taiwan and Macau.In return, HBM Alpha will receive up to $395 million, including upfront, development, regulatory, and commercial milestone payments, as well as tiered royalties on future net product sales.Additionally, HBM Alpha is entitled to a minority interest in the business partner, according to a Wednesday bourse filing.HBM9013 is an antibody program developed by the group for CRH-related disorders, including congenital adrenal hyperplasia, a group of diseases caused by gene mutations.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756168.USD","LU1267930573.SGD","CRH","LU1506573853.SGD","LU2041044095.USD","LU1019632923.USD","LU1863844665.USD","BK1583","BK1574","LU0310800379.SGD","LU2298321311.HKD","LU1019634622.SGD","LU1880398554.USD","LU0314106906.USD","LU0708994859.HKD","LU0029864427.USD","LU1863844749.USD","LU1291149836.SGD","LU0868494708.USD","BK4011","LU1880398471.USD","02142","LU2463526074.USD","BK1161","GB00BDT5M118.USD","LU2360108059.USD","LU0238689110.USD","BK4185","LU0128525929.USD","LU0942090050.USD","LU1039938227.USD","LU0868494617.USD","LU1035777561.USD","LU1093756325.SGD","JYNT","LU2092937221.SGD"],"gpt_icon":0},{"id":"2514388147","title":"Calculating The Fair Value Of JD Health International Inc. (HKG:6618)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514388147","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514388147?lang=en_us&edition=fundamental","pubTime":"2025-02-26 11:48","pubTimestamp":1740541696,"startTime":"0","endTime":"0","summary":"Key Insights Using the 2 Stage Free Cash Flow to Equity, JD Health International fair value estimate is HK$42.50...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/4422000-choice1-main-header/1585186589176","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4422000-choice1-main-header/1585186589176"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/consumer-retailing/hkg-6618/jd-health-international-shares/news/calculating-the-fair-value-of-jd-health-international-inc-hk-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4505","BK4531","LU0244354667.USD","LU0588546209.SGD","BK4579","BK4524","LU0326950275.SGD","FCF","BK1247","LU1688375341.USD","BK4558","LU1880383366.USD","BK4504","DCF","IE00BGV7N243.SGD","06618","IE0008368742.USD","BK1571","86618","LU0463099449.HKD","SG9999002463.SGD","BK4211","LU0456827905.SGD","BK1589","BK4503","LU1188198961.HKD","BK4526","LU0051755006.USD","BK4509","BK4122","BK1583","BK1515","BK4100","BK4551","BK4585","LU0307460666.USD","BK1591","LU0106959298.USD","BK1142","BK4588","BK4220","TV"],"gpt_icon":1},{"id":"2514881402","title":"Investors Met With Slowing Returns on Capital At Xtep International Holdings (HKG:1368)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514881402","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514881402?lang=en_us&edition=fundamental","pubTime":"2025-02-26 11:01","pubTimestamp":1740538883,"startTime":"0","endTime":"0","summary":"If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/4131000-choice1-main-header/1585186707756","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4131000-choice1-main-header/1585186707756"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/consumer-durables/hkg-1368/xtep-international-holdings-shares/news/investors-met-with-slowing-returns-on-capital-at-xtep-intern-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1512","BK1583","EBIT","BK1502","BK4211","BK1168","ISBC","01368"],"gpt_icon":0},{"id":"2514096805","title":"Hansoh Pharmaceutical Group's Anti-Hives Capsule Obtains Chinese Regulator's Approval for Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2514096805","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514096805?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:50","pubTimestamp":1740487802,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group's  HS-10561 capsules obtained China's National Medical Products Administration's approval for clinical trials to be tested for spontaneous hives, a Tuesday bourse filing said.The capsules, Category 1 small molecule Bruton's tyrosine kinase inhibitor  HS-10561, are jointly developed by the group and Guangzhou Lupeng Pharmaceutical.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1589","03692","BK1191","BK1583"],"gpt_icon":0},{"id":"2514950670","title":"Chinese Regulator Designates Hansoh Pharmaceutical Group's Injection as Breakthrough-Therapy Drug for Bone Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2514950670","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514950670?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:46","pubTimestamp":1740487571,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group's  HS-20093 for injection obtained China's National Medical Products Administration's  approval to be added as a breakthrough-therapy-designated drug for the treatment of patients with osteosarcoma, a type of bone cancer, a Tuesday bourse filing said.The Chinese regulator approved the drug for the treatment of patients who have progressed on at least two prior lines of therapy.HS-20093, also known as GSK5764227, is a B7-H3-targeted antibody-drug conjugate that is being developed in multiple clinical studies of small-cell lung cancer, head and neck cancers, and other solid tumors.The injection has also been granted breakthrough therapy designation by NMPA previously for lung cancer and from the US Food and Drug Administration for the treatment of relapsed or refractory extensive-stage small-cell lung cancer, ES-SCLC.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","BK1191","03692","BK1589"],"gpt_icon":0},{"id":"2514909332","title":"BRIEF-Hansoh Pharmaceutical Says NMPA Granted Approval For HS-20093","url":"https://stock-news.laohu8.com/highlight/detail?id=2514909332","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514909332?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:13","pubTimestamp":1740485624,"startTime":"0","endTime":"0","summary":"BRIEF-Hansoh Pharmaceutical Says NMPA Granted Approval For HS-20093Feb 25 (Reuters) - Hansoh Pharmaceutical 3692.HK:NMPA GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093Further company coverage: 3692.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG0C3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1583","03692","BK1589"],"gpt_icon":0},{"id":"2514641210","title":"BRIEF-Hansoh Pharmaceutical Receives Clinical Trial Approval For Hs-10561 Capsules Issued By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2514641210","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514641210?lang=en_us&edition=fundamental","pubTime":"2025-02-25 18:57","pubTimestamp":1740481033,"startTime":"0","endTime":"0","summary":"BRIEF-Hansoh Pharmaceutical Receives Clinical Trial Approval For Hs-10561 Capsules Issued By NMPAFeb 25 (Reuters) - Hansoh Pharmaceutical Group Company Ltd 3692.HK:CLINICAL TRIAL APPROVAL FOR HS-10561 CAPSULES ISSUED BY NMPAFurther company coverage: 3692.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG0JN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692","BK1589","BK1583","BK1191"],"gpt_icon":0},{"id":"2514406416","title":"Hansoh Pharmaceutical - Nmpa Granted Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate Hs-20093","url":"https://stock-news.laohu8.com/highlight/detail?id=2514406416","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514406416?lang=en_us&edition=fundamental","pubTime":"2025-02-25 18:55","pubTimestamp":1740480957,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG0C3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK1589","03692","BK1583"],"gpt_icon":0},{"id":"2514646100","title":"Hansoh Pharmaceutical -  Clinical Trial Approval for Hs-10561 Capsules Issued by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2514646100","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514646100?lang=en_us&edition=fundamental","pubTime":"2025-02-25 18:49","pubTimestamp":1740480596,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG0JN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK1589","BK1583","03692"],"gpt_icon":0},{"id":"2514706637","title":"Genor Biopharma - Co and Target Are in Course of Preparing New Listing Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2514706637","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514706637?lang=en_us&edition=fundamental","pubTime":"2025-02-25 17:54","pubTimestamp":1740477271,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PF25N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","06998","BK1574","BK1583"],"gpt_icon":0},{"id":"2514062795","title":"The Returns At China Resources Beer (Holdings) (HKG:291) Aren't Growing","url":"https://stock-news.laohu8.com/highlight/detail?id=2514062795","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514062795?lang=en_us&edition=fundamental","pubTime":"2025-02-25 08:13","pubTimestamp":1740442437,"startTime":"0","endTime":"0","summary":"Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/5111000-choice2-main-header/1585186902639","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5111000-choice2-main-header/1585186902639"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/food-beverage-tobacco/hkg-291/china-resources-beer-holdings-shares/news/the-returns-at-china-resources-beer-holdings-hkg291-arent-gr-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1794554557.SGD","SG9999006514.SGD","BK1583","00291","IE00B543WZ88.USD","IE00BPRC5H50.USD","BK1521","80291","IE00B5MMRT66.SGD","EBIT","CRHKY","IE00B031HY20.USD","LU0359202008.SGD","BK1180","BK1570","IE0008368742.USD","IE00B0169L03.USD","IE0008369823.USD","IE00B29SXG58.USD","LU1328615791.USD","BK1589","LU1023057109.AUD","LU0359201612.USD","BK1578","LU1720050803.USD","BK1510","BK1604"],"gpt_icon":0}],"pageSize":16,"totalPage":5,"pageCount":3,"totalSize":70}]}}